Navigation Links
Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc.
Date:4/1/2008

Reflects Full Scope of Integrated Global Services

CAMBRIDGE, Mass., April 1, 2008 /PRNewswire/ -- Abt Associates Clinical Trials today launches under a new name, Abt Bio-Pharma Solutions, Inc., a wholly owned subsidiary of Abt Associates Inc. The company will continue to provide custom strategic, research and communication solutions for the pharmaceutical, biotechnology, medical device and diagnostics industries utilizing a team approach that blends decades of experience with wide ranging technical and therapeutic area expertise.

Abt Bio-Pharma Solutions (ABS) offers a wide range of integrated services across the product lifecycle, including health economics and outcomes research, registries and other real world studies, clinical trials, biometrics and marketing consulting and research. Experienced professional staff lead cross-functional teams that are better able to address the complex issues facing the bio-pharma industry. Sponsors find that this integrated, collaborative approach promotes cost- and time-effective solutions to their business problems, with the result that the organization has grown 30 percent over the past year.

"ABS helps sponsors achieve success for their products in a very competitive marketplace," said Steven Fosburg, Executive Vice President and Managing Director of ABS. "We will leverage the increased flexibility that our new organization affords to invest in staff and resources to meet the expanding needs of our global client base without sacrificing any of the scientific rigor or timeliness that we are known for." ABS will open an office in Basel, Switzerland in May 2008.

Abt Associates has been a leader in healthcare-related research since 1965. "Abt Associates has a strong commitment to improving the health of people and communities around the world," said Wendell J. Knox, President and CEO of Abt Associates. "Abt Bio-Pharma Solutions is well positioned to respond to the clinical research and marketing challenges our clients face as they bring new products and solutions to market." As a subsidiary of Abt Associates, ABS is able to call on the company's extensive research services, knowledge base and technical expertise.

Abt Associates applies scientific research, technical assistance and consulting expertise to a wide range of social, economic and health policy issues; international development; bio-pharma industry issues; and complex business problems. Founded in 1965, the company provides services to U.S. federal, state and local governments; universities and foundations; media; and major corporations. Its staff of over 1,000 is located in Cambridge, Lexington (Abt Bio-Pharma Solutions, Inc.), and Hadley, Massachusetts; Bethesda, Maryland; Durham, North Carolina; Chicago Illinois; New York, New York (SRBI), and in Africa, Asia, Central Asia, Europe, Latin America, and the Middle East.


'/>"/>
SOURCE Abt Associates
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NSF International Acquires David Begg Associates
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
4. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
5. QED International Associates Announces Changes to the HealthShares(TM) Composite, HealthShares(TM) Cancer and HealthShares(TM) Neuroscience Indexes
6. QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Respiratory/Pulmonary Indexes
7. Halogen Receives High Ratings from Bersin & Associates - Company recognized as a market leader, and receives praise for outstanding customer satisfaction
8. QED International Associates Announces Changes to the HealthShares(TM) Dermatology and Wound Care Index
9. Lambert, Edwards & Associates Named Agency of Record for The West Michigan Science & Technology Initiative
10. QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes (As Revised)
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. ... STACS DNA as a Field Application Specialist. , “I am thrilled that Dr. ... STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings a ...
Breaking Biology Technology:
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):